Kissei Pharmaceutical

Kissei Pharmaceutical KSPHF Stock

$24.50   0.000000%
Add to favorites
Market Cap
$1.02B
LOW - HIGH [24H]
$30.28 - $30.28
VOLUME [24H]
$100.00
P/E Ratio
14.41
Earnings per share
$1.70
ISIN
JP3240600001
Price   Prediction

Kissei Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

Kissei Pharmaceutical (KSPHF) stock price today is 24.5 USD on OTC Markets OTCPK (0% on the day). Updated .

Kissei Pharmaceutical KSPHF Financial and Trading Overview

Kissei Pharmaceutical stock price 24.5 USD
Previous Close 24.5 USD
Open 30.28 USD
Bid 27.39 USD x 10000
Ask 28.51 USD x 30000
Day's Range 30.28 - 30.28 USD
52 Week Range 24.5 - 31.9 USD
Volume 100 USD
Avg. Volume 9 USD
Market Cap 1.02B USD
Beta (5Y Monthly) -0.133
PE Ratio (TTM) 14.411764
EPS (TTM) 1.7 USD
Forward Dividend & Yield 0.81 (3.32%)
Ex-Dividend Date March 30, 2027
1y Target Est N/A

KSPHF Valuation Measures

Enterprise Value -49961410560 USD
Trailing P/E 14.411764
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.010528943
Price/Book (mrq) 0.70899826
Enterprise Value/Revenue -0.515
Enterprise Value/EBITDA -4.817

Trading Information

Kissei Pharmaceutical Stock Price History

Beta (5Y Monthly) -0.133
52-Week Change -2.39%
S&P500 52-Week Change 12.00%
52 Week High 31.9 USD
52 Week Low 24.5 USD
50-Day Moving Average 24.88 USD
200-Day Moving Average 25.69 USD

KSPHF Share Statistics

Avg. Volume (3 month) 9 USD
Avg. Daily Volume (10-Days) 0 USD
Shares Outstanding 41.72M
Float 35.05M
Short Ratio N/A
% Held by Insiders 21.67%
% Held by Institutions 28.09%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 60
Trailing Annual Dividend Yield 244.89%
5 Year Average Dividend Yield 237.00%
Payout Ratio 0.4664
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 11.52%
Operating Margin (ttm) 5.77%
Gross Margin 46.19%
EBITDA Margin 10.68%

Management Effectiveness

Return on Assets (ttm) 1.32%
Return on Equity (ttm) 5.12%

Income Statement

Revenue (ttm) 97.08B USD
Revenue Per Share (ttm) 2338.65 USD
Quarterly Revenue Growth (yoy) -6.50%
Gross Profit (ttm) 44.84B USD
EBITDA 10.37B USD
Net Income Avi to Common (ttm) 11.19B USD
Diluted EPS (ttm) 1.7
Quarterly Earnings Growth (yoy) -85.70%

Balance Sheet

Total Cash (mrq) 53.69B USD
Total Cash Per Share (mrq) 1286.42 USD
Total Debt (mrq) 1.25B USD
Total Debt/Equity (mrq) 0.55 USD
Current Ratio (mrq) 6.142
Book Value Per Share (mrq) 34.555798

Cash Flow Statement

Operating Cash Flow (ttm) -8945000448 USD
Levered Free Cash Flow (ttm) -11471500288 USD

Profile of Kissei Pharmaceutical

Country United States
State N/A
City Matsumoto
Address 19-48, Yoshino
ZIP 399-8710
Phone 81 2 6325 9081
Website https://www.kissei.co.jp
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 1786

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, that is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0914 that is in Phase I clinical trial to treat Graves' disease; KPS-0373, that is in Phase III clinical trial to treat Spinocerebellar degeneration; KSP- 0576 that is in Phase I clinical trial to treat interstitial cystitis and bladder pain syndrome; and KSP-0930, which is in Phase I clinical trial to treat Narcolepsy. It also develops Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; purchases and sells related materials; and offers system development and information processing, facility and equipment management, and information gathering and development support services. Further, it engages in information equipment rentals; insurance agency business; manufactures and sells noodles; construction contracting; and computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.

Q&A For Kissei Pharmaceutical Stock

What is a current KSPHF stock price?

Kissei Pharmaceutical KSPHF stock price today per share is 24.5 USD.

How to purchase Kissei Pharmaceutical stock?

You can buy KSPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Kissei Pharmaceutical?

The stock symbol or ticker of Kissei Pharmaceutical is KSPHF.

Which industry does the Kissei Pharmaceutical company belong to?

The Kissei Pharmaceutical industry is Drug Manufacturers - Specialty & Generic.

How many shares does Kissei Pharmaceutical have in circulation?

The max supply of Kissei Pharmaceutical shares is 41.72M.

What is Kissei Pharmaceutical Price to Earnings Ratio (PE Ratio)?

Kissei Pharmaceutical PE Ratio is 14.41176400 now.

What was Kissei Pharmaceutical earnings per share over the trailing 12 months (TTM)?

Kissei Pharmaceutical EPS is 1.7 USD over the trailing 12 months.

Which sector does the Kissei Pharmaceutical company belong to?

The Kissei Pharmaceutical sector is Healthcare.

$2.13T
Total marketcap
$77.87B
Total volume
BTC 57.94%   •   ETH 9.92%
Dominance
Select currency